Your session is about to expire
← Back to Search
Venetoclax + Azacitidine for Leukemia
Study Summary
This trial will test a new treatment for people with leukemia who have not responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 389 Patients • NCT02005471Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can take care of myself and am up and about more than half of my waking hours.I will use birth control from the start of the study drug until 90 days after the last dose.I am a pre-menopausal woman who agrees to use two forms of birth control or abstain from sex.I have been treated for MDS or AML, but ATRA for suspected APL doesn't disqualify me.I cannot take medicine by mouth due to a digestive condition.I am currently being treated for a serious infection that is not under control.I am HIV positive.I am willing to undergo strong initial chemotherapy.I have had cancer before, but it meets the study's exceptions.I do not have symptoms of brain or spinal cord disease.My leukemia is confirmed as non-APL and AML according to WHO standards.I am between 18 and 59 years old.My liver functions are within normal limits, unless affected by leukemia.My leukemia is considered high-risk according to European standards.My kidneys work well enough, with a creatinine clearance rate of at least 30 mL/min.I have not received any treatment for AML.I haven't taken steroids or certain strong medications for cancer in the last week.
- Group 1: Azacitidine and Venetoclax
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any unfilled positions for volunteers in this experiment?
"After checking clinicaltrials.gov, it appears that this trial is still looking for participants. The listing was first uploaded on November 14th, 2018 and the last update was on August 22nd, 2022."
Does Venetoclax carry any serious side effects?
"Even though there is no data demonstrating efficacy, Venetoclax received a safety score of 2 because Phase 2 trials offer evidence that it is not harmful."
Does this research involve middle-aged or elderly patients?
"This clinical study includes an age range of 18 to 59 years old, as denoted by the inclusion criteria."
Is there a precedent for using Venetoclax in this way?
"350 clinical trials are being conducted worldwide for Venetoclax. Of these, 55 have progressed to Phase 3. Many of the trials originate from Toronto, but there are 11288 locations running active trials."
To what purpose is Venetoclax most often employed?
"Venetoclax has a wide range of potential applications including induction chemotherapy, treatment of refractory anemias, and management of leukemia."
How many subjects are being admitted into this research project?
"The information available on clinicaltrials.gov verifies that this study is actively recruiting patients. The listing was first created on November 14th, 2018 and updated as recently as August 22nd, 2020. Currently, 36 individuals are needed to fill the slots at a single site location."
Could I join this clinical trial?
"This leukemia study has 36 slots available for patients aged 18-59."
Share this study with friends
Copy Link
Messenger